-
公开(公告)号：US10364267B2
公开(公告)日：2019-07-30
申请号：US15439358
申请日：2017-02-22
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Jiang Long , Guoyou Xu , Peng Dai , Ruichao Shen , Xuechao Xing , Jing He
Abstract: The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
-
公开(公告)号：US20170334893A1
公开(公告)日：2017-11-23
申请号：US15597417
申请日：2017-05-17
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Jun Ma , Bin Wang , Yong He , Xuechao Xing , Ruichao Shen , Brett Granger , Jing He , Jiang Long , Guoqiang Wang
IPC: C07D413/12 , C07D261/08
CPC classification number: C07D413/12 , A61K31/42 , C07D261/08
Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20170304270A1
公开(公告)日：2017-10-26
申请号：US15497268
申请日：2017-04-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Brett Granger , Ruichao Shen , Xuechao Xing , Bin Wang , Jun Ma , Jing He , Jiang Long , Yong He , Guoqiang Wang
IPC: A61K31/42 , C07D261/06 , C07D413/04 , C07D413/12
CPC classification number: A61K31/42 , C07D261/06 , C07D261/08 , C07D413/04 , C07D413/12
Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
54.发明申请公开(公告)号：US20170240587A1
公开(公告)日：2017-08-24
申请号：US15439531
申请日：2017-02-22
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yat Sun Or , Jing He , Guoqiang Wang , Xuechao Xing
IPC: C07J43/00
CPC classification number: C07J43/003 , A61K31/58 , C07J9/005 , C07J41/0061
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
-
55.发明申请公开(公告)号：US20160130297A1
公开(公告)日：2016-05-12
申请号：US14934122
申请日：2015-11-05
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Guoqiang Wang , Ruichao Shen , Xuechao Xing
CPC classification number: C07J41/0061 , C07J41/0088 , C07J43/003
Abstract: The present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.
Abstract translation: 本发明涉及式（I）化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8和m如本文所定义，包含这些化合物的药物组合物和使用方法 的这些化合物用于治疗TGR5介导的疾病或病症。
-
Patent Agency Ranking
公开(公告)号：US11555032B2
公开(公告)日：2023-01-17
申请号：US16871551
申请日：2020-05-11
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Jun Ma , Bin Wang , Ruichao Shen , Xuechao Xing , Yong He , Yat Sun Or
IPC: C07D417/12 , C07D413/12 , C07D417/14 , C07D261/08 , C07D413/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US11420976B2
公开(公告)日：2022-08-23
申请号：US17155159
申请日：2021-01-22
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yong He , Xuechao Xing , Guoqiang Wang , Ruichao Shen , Brett Granger , Jiang Long , Yat Sun Or
IPC: C07D491/048 , A61K45/06
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US20220162231A1
公开(公告)日：2022-05-26
申请号：US17531844
申请日：2021-11-22
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jun Ma , Yong He , Xuechao Xing , Hui Cao , Xuri Gao , Xiaowen Peng , Joseph D. Panarese , Yat Sun Or
IPC: C07D519/00
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20220119398A1
公开(公告)日：2022-04-21
申请号：US17503626
申请日：2021-10-18
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yat Sun Or , Yong He , Kevin McGrath , Ruichao Shen , Adam Szymaniak , Xuechao Xing , In Jong Kim , Guoqiang Wang
IPC: C07D491/048 , A61P31/14 , A61K45/06
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US20210261600A1
公开(公告)日：2021-08-26
申请号：US17186447
申请日：2021-02-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
-
-
-
-
-
-
-
-
Search Results
93
records
(took 0.024 seconds)
